Syndax Pharmaceuticals Inc (SNDX)
18.94
-0.04
(-0.21%)
USD |
NASDAQ |
Nov 04, 16:00
18.50
-0.44
(-2.32%)
After-Hours: 20:00
Syndax Pharmaceuticals Enterprise Value: 1.179B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.179B |
| November 01, 2024 | 1.183B |
| October 31, 2024 | 1.173B |
| October 30, 2024 | 1.178B |
| October 29, 2024 | 1.191B |
| October 28, 2024 | 1.202B |
| October 25, 2024 | 1.163B |
| October 24, 2024 | 1.184B |
| October 23, 2024 | 1.145B |
| October 22, 2024 | 1.198B |
| October 21, 2024 | 1.230B |
| October 18, 2024 | 1.245B |
| October 17, 2024 | 1.260B |
| October 16, 2024 | 1.260B |
| October 15, 2024 | 1.248B |
| October 14, 2024 | 1.254B |
| October 11, 2024 | 1.196B |
| October 10, 2024 | 1.116B |
| October 09, 2024 | 1.127B |
| October 08, 2024 | 1.132B |
| October 07, 2024 | 1.122B |
| October 04, 2024 | 1.169B |
| October 03, 2024 | 1.158B |
| October 02, 2024 | 1.222B |
| October 01, 2024 | 1.260B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.206B |
| September 27, 2024 | 1.175B |
| September 26, 2024 | 1.113B |
| September 25, 2024 | 1.101B |
| September 24, 2024 | 1.123B |
| September 23, 2024 | 1.094B |
| September 20, 2024 | 1.122B |
| September 19, 2024 | 1.153B |
| September 18, 2024 | 1.099B |
| September 17, 2024 | 1.105B |
| September 16, 2024 | 1.116B |
| September 13, 2024 | 1.195B |
| September 12, 2024 | 1.099B |
| September 11, 2024 | 1.127B |
| September 10, 2024 | 1.168B |
| September 09, 2024 | 1.168B |
| September 06, 2024 | 1.193B |
| September 05, 2024 | 1.236B |
| September 04, 2024 | 1.240B |
| September 03, 2024 | 1.316B |
| August 30, 2024 | 1.316B |
| August 29, 2024 | 1.288B |
| August 28, 2024 | 1.326B |
| August 27, 2024 | 1.339B |
| August 26, 2024 | 1.349B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
110.96M
Minimum
Nov 14 2019
1.677B
Maximum
Jul 16 2024
798.73M
Average
757.14M
Median
Nov 24 2020
Enterprise Value Benchmarks
| Incyte Corp | 12.82B |
| Trevena Inc | 16.60M |
| Bristol-Myers Squibb Co | 154.18B |
| Arcus Biosciences Inc | 453.61M |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.06M |
| Revenue (Quarterly) | 3.50M |
| Total Expenses (Quarterly) | 77.72M |
| EPS Diluted (Quarterly) | -0.80 |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -17.85% |
| Normalized Earnings Yield | -17.85 |